9 / 18
Page 33
Biochemistry & Molecular Biology Journal
ISSN: 2471-8084
Internat i ona l Conference on
Biotechnology, Biomarkers
& Systems Biology
M a r c h 0 4 - 0 5 , 2 0 1 9
Am s t e r d a m , N e t h e r l a n d s
Biotechnology, Biomarkers & Systems Biology 2019
E
arly work uncovered HCG1745306 isoform CRA-a, and histone H1.2 as
potential specific plasma biomarkers for the identification of patients with
early ER
+
(estrogen receptor-positive) breast cancer. However, while these
markers were absent in controls, the results were obtained from only two
patients and therefore require verification in a larger patient cohort. Moreover,
in another preliminary study, we identified potential extracellular vesicles
(EV) factors which might serve as biomarkers for predictive and diagnostic
purposes in metastatic breast cancer. Plasma samples from seven different
metastatic and non-metastatic ER
+
breast cancer patients were collected,
EV were isolated and their protein content analyzed by mass spectrometry
and FunRich analysis. In this study, we found several putative plasma EV
biomarkers for metastatic ER
+
breast cancer prediction and diagnosis, such
as serum amyloid A1, known to promote widespread metastasis in a breast
cancer animal model. In conjunction with academic and clinical colleagues
from the Department of Biomedical Sciences at the University of Hull and
Castle Hill Hospital, we propose to examine the pathophysiological role of the
proteins found in the original works using tissue samples from patients with
a confirmed diagnosis of breast cancer compared to adjacent benign breast
tissues. If the initial results are confirmed, we will determine if these markers
can be identified in whole blood samples from a larger cohort of patients with
breast cancer. These projects have the potential to identify blood biomarkers
for early breast cancer improving the specificity of mammography, allowing
patients to be selected for auxiliary imaging based on the presence of specific
biomarkers in the blood and to identify with certainty which early precursor
lesions will progress to malignancy. Also, they have the potential to be used
to identify both early breast cancer and whether the disease has metastasized
to other sites. If confirmed in a large patient cohort, the biomarkers could be
isolated and incorporated into a non-invasive test such as a lateral flow device
that could be used for the detection of patients with early and metastatic breast
cancer and to identify the sites to which the cancer has metastasized. This
would help clinicians decide which patients will benefit of adjuvant therapy. If
the original findings cannot be replicated, we will search for suitable biomarkers
in urine or saliva samples or plasma samples using 2D gel electrophoresis and
the scioDiscover platform.
Biography
Ana Pedro working as Pharmacist in Rowland’s Pharmacy, she
works in the development of test kits for circulating biomarkers
for early and advanced breast cancer to be commercialized in
community pharmacies. Also undertaken community clinical
pharmacy research work and looking forward to develop PGDs
and educational materials to pharmacists and bring overseas
pharmacists to work in UK.
anapedrolaboratories@gmail.comDevelopment of circulating biomarkers for early and
advanced breast cancer
Ana Pedro
2,3
, Rod Tucker
1,2
, Michael J Lind
3
and Barbara Guinn
3
1
Robert Gordon University, UK
2
Biomarkers Ltd, UK
3
University of Hull, UK
Ana Pedro et al., Biochem Mol biol J 2019, Volume:5
DOI: 10.21767/2471-8084-C1-023